Ca2+ Feedback on “Quantal” Ca2+Release Involving Ryanodine Receptors
- Departments of 1Physiology and Biophysics (C.D., P.P.) and2Pharmacology and Toxicology (P.P.), University of Texas Medical Branch, Galveston, Texas 77555-0641
Abstract
The influence of luminal and cytoplasmic Ca2+ on the ability of ryanodine-sensitive stores to undergo multiple partial (“quantal”) releases has been assessed. Increased luminal Ca2+ levels do indeed modulate sarcoplasmic reticulum Ca2+ release by lowering the threshold agonist concentration required to elicit release, but the decrease in luminal Ca2+ that accompanies a partial release is not sufficient by itself to terminate release. Similarly, an increase in cytoplasmic Ca2+ lowers the threshold agonist concentration required to elicit release; thus, the bulk cytoplasmic Ca2+ levels attained during a release would only stimulate further release, not terminate it before it reached completion. Very high cytoplasmic Ca2+ levels (1–3 mm) also triggered release but were unable to terminate release before reaching completion. Thus, even the high local cytoplasmic Ca2+ concentration that might accompany release would also not terminate release. It is concluded that Ca2+ feedback can modulate release through ryanodine receptors but that it does not account for the properties of quantal release. The low affinity inhibitor tetracaine induces a decrease in the extent of release that cannot be explained solely by heterogeneous caffeine sensitivity of the stores. The results are interpreted in terms of a scheme that includes (i) heterogeneous sensitivity of stores, conferred in part by differences in luminal Ca2+ content and (ii) adaptive behavior on the part of individual ryanodine receptors.
Footnotes
-
Send reprint requests to: Dr. Philip Palade, Department of Physiology and Biophysics, University of Texas Medical Branch, Galveston, TX 77555-0641. E-mail: philip.palade{at}utmb.edu
-
This work was supported by National Institutes of Health Grant AR43200.
- Abbreviations:
- CICR
- Ca2+-induced Ca2+ release
- EGTA
- ethylene glycol bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
- InsP3
- inositol-1,4,5-trisphosphate
- MOPS
- 3-(N-morpholino)propanesulfonic acid
- RyR
- ryanodine receptor
- SR
- sarcoplasmic reticulum
-
- Received May 19, 1997.
- Accepted August 26, 1997.
- The American Society for Pharmacology and Experimental Therapeutics



